Company: BIAF
Filing Date: 2025-09-30
Form Type: 424B4
Source: 0001493152-25-016338
Chunk: 19

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-30
Form: 424B4
Chunk 19
---
 per share after giving effective to this offering |     | $ |  1.19 |   |
| Dilution per share to the new investor in this offering                                         |     | $ |  1.31 |   |

The number of shares of Common Stock to be outstanding immediately after this offering is based on 948,651 shares of Common Stock outstanding as of June 30, 2025, and excludes, as of such date:

| ● | 939,680                                                                                                                            
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $41.60   
 per share;                                                                                                                         |
| ● | 9,530                                                                                                                              
 shares of Common Stock issuable upon the exercise of stock options issued under our equity incentive plans with a weighted average 
 exercise price equal to $207.30 per share; and                                                                                     |
| ● | 41,908                                                                                                                             
 shares of our Common Stock that are reserved for equity awards that may be granted under our 2024 Equity Incentive Plan.           |

| 15 |

<div align='center'>DESCRIPTION OF SECURITIES</div>

Authorized Capital Stock

We are currently authorized to issue up to 350,000,000 shares of Common Stock, par value $0.007 per share, and 20,000,000 shares of Preferred Stock, par value $0.001 per share. As permitted by the Company’s Charter, the Company has designated (i) 5,400,000 shares of Preferred Stock as “Series A Convertible Preferred Stock,” par value $0.001 per share (the “Series A Preferred Stock”), of which no shares are outstanding, and (ii) 990 shares of Preferred Stock as “Series B Convertible Preferred Stock,” par value $0.001 per share (the “Series B Preferred Stock”), of which 715.5 shares are outstanding.

Common Stock

Voting Rights

Holders of our Common Stock are entitled to cast one vote for each share held of record on all matters presented to the stockholders. Holders of our Common Stock have no cumulative voting rights.

Dividend Rights

The Board is not obligated to declare a dividend, has never declared or paid cash dividends on its Common Stock, and does not anticipate paying dividends on our Common Stock for the foreseeable future.

Rights upon Liquidation

In the event of our liquidation, dissolution, or winding up, either voluntary or involuntary, subject to the rights and preferences that may apply to any